Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Serum lactate as a novel potential biomarker in multiple sclerosis.

Amorini AM, Nociti V, Petzold A, Gasperini C, Quartuccio E, Lazzarino G, Di Pietro V, Belli A, Signoretti S, Vagnozzi R, Lazzarino G, Tavazzi B.

Biochim Biophys Acta. 2014 Jul;1842(7):1137-43. doi: 10.1016/j.bbadis.2014.04.005. Epub 2014 Apr 13.

2.

Serum homocysteine levels in relation to clinical progression in multiple sclerosis.

Teunissen CE, Killestein J, Kragt JJ, Polman CH, Dijkstra CD, Blom HJ.

J Neurol Neurosurg Psychiatry. 2008 Dec;79(12):1349-53. doi: 10.1136/jnnp.2008.151555. Epub 2008 Aug 1.

PMID:
18676406
3.

Serum NSE level and disability progression in multiple sclerosis.

Koch MW, George S, Wall W, Wee Yong V, Metz LM.

J Neurol Sci. 2015 Mar 15;350(1-2):46-50. doi: 10.1016/j.jns.2015.02.009. Epub 2015 Feb 11.

PMID:
25686504
4.

Uric acid: a potential biomarker of multiple sclerosis and of its disability.

Moccia M, Lanzillo R, Palladino R, Russo C, Carotenuto A, Massarelli M, Vacca G, Vacchiano V, Nardone A, Triassi M, Morra VB.

Clin Chem Lab Med. 2015 Apr;53(5):753-9. doi: 10.1515/cclm-2014-0744.

PMID:
25241733
5.

Cerebrospinal fluid evidence of increased extra-mitochondrial glucose metabolism implicates mitochondrial dysfunction in multiple sclerosis disease progression.

Regenold WT, Phatak P, Makley MJ, Stone RD, Kling MA.

J Neurol Sci. 2008 Dec 15;275(1-2):106-12. doi: 10.1016/j.jns.2008.07.032. Epub 2008 Sep 9.

6.

Hypointense lesions on T1-weighted spin-echo magnetic resonance imaging: relation to clinical characteristics in subgroups of patients with multiple sclerosis.

van Walderveen MA, Lycklama A Nijeholt GJ, Adèr HJ, Jongen PJ, Polman CH, Castelijns JA, Barkhof F.

Arch Neurol. 2001 Jan;58(1):76-81.

PMID:
11176939
7.

Insulin-like growth factor (IGF)-I and IGF-binding protein-3 serum levels in relapsing-remitting and secondary progressive multiple sclerosis patients.

Lanzillo R, Di Somma C, Quarantelli M, Ventrella G, Gasperi M, Prinster A, Vacca G, Pivonello C, Orefice G, Colao A, Morra VB.

Eur J Neurol. 2011 Dec;18(12):1402-6. doi: 10.1111/j.1468-1331.2011.03433.x. Epub 2011 May 18.

PMID:
21585623
8.

Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis.

Tutuncu M, Tang J, Zeid NA, Kale N, Crusan DJ, Atkinson EJ, Siva A, Pittock SJ, Pirko I, Keegan BM, Lucchinetti CF, Noseworthy JH, Rodriguez M, Weinshenker BG, Kantarci OH.

Mult Scler. 2013 Feb;19(2):188-98. doi: 10.1177/1352458512451510. Epub 2012 Jun 26.

9.

Gray matter atrophy correlates with MS disability progression measured with MSFC but not EDSS.

Rudick RA, Lee JC, Nakamura K, Fisher E.

J Neurol Sci. 2009 Jul 15;282(1-2):106-11. doi: 10.1016/j.jns.2008.11.018. Epub 2008 Dec 19.

10.

Fast whole-brain three-dimensional macromolecular proton fraction mapping in multiple sclerosis.

Yarnykh VL, Bowen JD, Samsonov A, Repovic P, Mayadev A, Qian P, Gangadharan B, Keogh BP, Maravilla KR, Jung Henson LK.

Radiology. 2015 Jan;274(1):210-20. doi: 10.1148/radiol.14140528. Epub 2014 Sep 10.

11.

Serum Compounds of Energy Metabolism Impairment Are Related to Disability, Disease Course and Neuroimaging in Multiple Sclerosis.

Lazzarino G, Amorini AM, Petzold A, Gasperini C, Ruggieri S, Quartuccio ME, Lazzarino G, Di Stasio E, Tavazzi B.

Mol Neurobiol. 2017 Nov;54(9):7520-7533. doi: 10.1007/s12035-016-0257-9. Epub 2016 Nov 8.

PMID:
27826747
12.

Brain and cord myelin water imaging: a progressive multiple sclerosis biomarker.

Kolind S, Seddigh A, Combes A, Russell-Schulz B, Tam R, Yogendrakumar V, Deoni S, Sibtain NA, Traboulsee A, Williams SC, Barker GJ, Brex PA.

Neuroimage Clin. 2015 Oct 3;9:574-80. doi: 10.1016/j.nicl.2015.10.002. eCollection 2015.

13.

Spinal cord atrophy in multiple sclerosis and relationship with disability across clinical phenotypes.

Bernitsas E, Bao F, Seraji-Bozorgzad N, Chorostecki J, Santiago C, Tselis A, Caon C, Zak I, Millis S, Khan O.

Mult Scler Relat Disord. 2015 Jan;4(1):47-51. doi: 10.1016/j.msard.2014.11.002. Epub 2014 Nov 18.

PMID:
25787052
14.

Serum prolactin level in patients with multiple sclerosis: a case control study.

Harirchian MH, Sahraian MA, Shirani A.

Med Sci Monit. 2006 Apr;12(4):CR177-80. Epub 2006 Mar 28.

PMID:
16572053
15.

CSF nitric oxide metabolites are associated with activity and progression of multiple sclerosis.

Rejdak K, Eikelenboom MJ, Petzold A, Thompson EJ, Stelmasiak Z, Lazeron RH, Barkhof F, Polman CH, Uitdehaag BM, Giovannoni G.

Neurology. 2004 Oct 26;63(8):1439-45.

PMID:
15505162
16.

Plasmatic oxidative stress biomarkers in multiple sclerosis: relation with clinical and demographic characteristics.

Pasquali L, Pecori C, Lucchesi C, LoGerfo A, Iudice A, Siciliano G, Bonuccelli U.

Clin Biochem. 2015 Jan;48(1-2):19-23. doi: 10.1016/j.clinbiochem.2014.09.024. Epub 2014 Oct 7.

PMID:
25300461
17.

Brain atrophy in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis: longitudinal quantitative analysis.

Ge Y, Grossman RI, Udupa JK, Wei L, Mannon LJ, Polansky M, Kolson DL.

Radiology. 2000 Mar;214(3):665-70.

PMID:
10715027
18.

Circulating microRNAs as biomarkers for disease staging in multiple sclerosis.

Gandhi R, Healy B, Gholipour T, Egorova S, Musallam A, Hussain MS, Nejad P, Patel B, Hei H, Khoury S, Quintana F, Kivisakk P, Chitnis T, Weiner HL.

Ann Neurol. 2013 Jun;73(6):729-40. doi: 10.1002/ana.23880. Epub 2013 Jul 8.

PMID:
23494648
19.

Sodium accumulation is associated with disability and a progressive course in multiple sclerosis.

Paling D, Solanky BS, Riemer F, Tozer DJ, Wheeler-Kingshott CA, Kapoor R, Golay X, Miller DH.

Brain. 2013 Jul;136(Pt 7):2305-17. doi: 10.1093/brain/awt149.

PMID:
23801742
20.

The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.

Ball S, Vickery J, Hobart J, Wright D, Green C, Shearer J, Nunn A, Cano MG, MacManus D, Miller D, Mallik S, Zajicek J.

Health Technol Assess. 2015 Feb;19(12):vii-viii, xxv-xxxi, 1-187. doi: 10.3310/hta19120.

Supplemental Content

Support Center